CA Patent

CA2976062C — Thymosin alpha 1 for use in treatment of cystic fibrosis

Assigned to Individual · Expires 2025-05-13 · 1y expired

What this patent protects

The present invention concerns Thymosin al¬ pha 1 (Tai) for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.

USPTO Abstract

The present invention concerns Thymosin al¬ pha 1 (Tai) for use in treatment of cystic fibrosis as a CFTR corrector, CFTR potentiator and anti-inflammatory agent.

Drugs covered by this patent

Kalydeco (IVACAFTOR) · Vertex Pharms Inc

Patent Metadata

Patent number: CA2976062C
Jurisdiction: CA
Classification: —
Expires: 2025-05-13
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.